Edgar Löffler

Nucletron BV designs, develops, and manufactures medical devices for the treatment of cancer. The company specializes in radiotherapy solutions, medical imaging, treatment planning and delivery, and specialized applicators. It also offers software solutions for training courses, technical courses, and clinical workshops. Nucletron was founded in 1975 and is headquartered in Veenendaal, the Netherlands.

Eckert & Ziegler BEBIG SA engages in the provision of medical devices. Its products include prostate seed brachytherapy, brain seed brachytherapy, high dose rate brachytherapy, ophthalmic brachytherapy and radiotherapy accessories. The company was founded on February 15, 1996, is headquartered in Seneffe, Belgium.

Eckert & Ziegler Bebig GmbH dvelops and manufactures equipment for cancer treatment. The company is headquartered in Berlin, Germany.

Part of Eckert & Ziegler Strahlen- und Medizintechnik AG, Eckert & Ziegler Isotope Products, Inc. is a provider of isotope technology for medical, scientific, and industrial use. The private company is based in Valencia, CA. The company specializes in radionuclides, radiosynthesis, and quality control equipment for effective treatment options for many types of cancer. The company also offers radiation sources for medical imaging, industrial control, and calibration. Frank Yeager has been the CEO of the company since 2001.

Eckert & Ziegler AG is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The private company has a global presence of subsidiaries in several regions and is based in Berlin, DE. With nearly 1,000 employees, the German company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The CEO of the company is Andreas Eckert.

NanoBrachyTech CJSC engages in development of nanotechnologies for treatment of cancer. It implements a project on production of micro sources and nanostructures for brachytherapy, based on silicon and phosphorus alloys, for treatment of primary and metastatic liver and pancreatic cancer. The company was founded on June 30, 2009 and is headquartered in Dubna, Russia.